| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11897-018-0381-0 |
| P698 | PubMed publication ID | 29468530 |
| P50 | author | James Januzzi | Q63144011 |
| P2093 | author name string | Nasrien E Ibrahim | |
| P2860 | cites work | Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis | Q27012693 |
| Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 | ||
| Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study | Q33165022 | ||
| Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. | Q33882750 | ||
| Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure | Q34324771 | ||
| Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials | Q34614873 | ||
| Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in | Q35011439 | ||
| Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials | Q37584696 | ||
| Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management | Q38077391 | ||
| Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). | Q38371676 | ||
| Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial | Q38371833 | ||
| BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial | Q38383948 | ||
| Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissi | Q39493213 | ||
| Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome | Q39734086 | ||
| Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality | Q42781665 | ||
| N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study | Q43156281 | ||
| Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial | Q43239377 | ||
| N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial | Q43549494 | ||
| Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure | Q43573505 | ||
| Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study | Q45119738 | ||
| Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure | Q46466518 | ||
| Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure | Q48023365 | ||
| Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long | Q48190480 | ||
| Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study | Q48194485 | ||
| Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony | Q48273698 | ||
| Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction | Q48563810 | ||
| The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure | Q48971321 | ||
| Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. | Q53612767 | ||
| Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients | Q60619537 | ||
| Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations | Q73736775 | ||
| 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society o | Q87967845 | ||
| P433 | issue | 2 | |
| P921 | main subject | heart failure | Q181754 |
| biomarker | Q864574 | ||
| P304 | page(s) | 37-43 | |
| P577 | publication date | 2018-04-01 | |
| P1433 | published in | Current heart failure reports | Q26842297 |
| P1476 | title | The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study | |
| P478 | volume | 15 |
| Q64108165 | Association between admission plasma 2-oxoglutarate levels and short-term outcomes in patients with acute heart failure: a prospective cohort study |
| Q92925812 | Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations |
| Q92292783 | Heart failure drug treatment |
| Q92377424 | Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications |
Search more.